|
Innovation Pathway Advances May Be Expanded Throughout Agency
CINCINNATI — Regulatory advances made during the Innovation Pathway 2.0 project to develop new treatments for end-stage renal disease may quickly be rolled throughout CDRH, center Director Jeffrey Shuren said Wednesday at the FDA/Xavier University MedCon Conference here.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives